|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Małkowski P, Pacholczyk M, Łagiewska B,
Adadyński L, Wasiak D, Kwiatkowski A, Chmura A and Czerwiński J:
Hepatocellular carcinoma - epidemiology and treatment. Przegl
Epidemiol. 60:731–740. 2006.(In Polish).
|
|
3
|
Belghiti J and Kianmanesh R: Surgical
treatment of hepatocellular carcinoma. HPB Oxf. 7:42–49. 2005.
View Article : Google Scholar
|
|
4
|
Lee PH, Lin WJ, Tsang YM, Hu RH, Sheu JC,
Lai MY, Hsu HC, May W and Lee CS: Clinical management of recurrent
hepatocellular carcinoma. Ann Surg. 222:670–676. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosenberg B, Vancamp L and Krigas T:
Inhibition of cell division in Escherichia coli by electrolysis
products from a platinum electrode. Nature. 205:698–699. 1965.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
|
|
7
|
Fuertes MA, Castilla J, Alonso C and Pérez
JM: Cisplatin biochemical mechanism of action: From cytotoxicity to
induction of cell death through interconnections between apoptotic
and necrotic pathways. Curr Med Chem. 10:257–266. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Asechi H, Hatano E, Nitta T, Tada M,
Iwaisako K, Tamaki N, Nagata H, Narita M, Yanagida A, Ikai I, et
al: Resistance to cisplatin-induced apoptosis via PI3K-dependent
survivin expression in a rat hepatoma cell line. Int J Oncol.
37:89–96. 2010.PubMed/NCBI
|
|
9
|
Drayton RM: The role of microRNA in the
response to cisplatin treatment. Biochem Soc Trans. 40:821–825.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Masaki T: MicroRNA and hepatocellular
carcinoma. Hepatol Res. 39:751–752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M,
et al: Combinatorial microRNA target predictions. Nat Genet.
37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar
|
|
13
|
Michael MZ, O’Connor SM, van Holst
Pellekaan NG, Young GP and James RJ: Reduced accumulation of
specific microRNAs in colorectal neoplasia. Mol Cancer Res.
1:882–891. 2003.PubMed/NCBI
|
|
14
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner
MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen
TD: Expression profiling identifies microRNA signature in
pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar
|
|
15
|
Takamizawa J, Konishi H, Yanagisawa K,
Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y,
et al: Reduced expression of the let-7 microRNAs in human lung
cancers in association with shortened postoperative survival.
Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gramantieri L, Ferracin M, Fornari F,
Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E,
Grazi GL, et al: Cyclin G1 is a target of miR-122a, a microRNA
frequently down-regulated in human hepatocellular carcinoma. Cancer
Res. 67:6092–6099. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wong QW, Lung RW, Law PT, Lai PB, Chan KY,
To KF and Wong N: MicroRNA-223 is commonly repressed in
hepatocellular carcinoma and potentiates expression of Stathmin1.
Gastroenterology. 135:257–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Varnholt H, Drebber U, Schulze F,
Wedemeyer I, Schirmacher P, Dienes HP and Odenthal M: MicroRNA gene
expression profile of hepatitis C virus-associated hepatocellular
carcinoma. Hepatology. 47:1223–1232. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Masaki T, Tokuda M, Yoshida S, Nakai S,
Morishita A, Uchida N, Funaki T, Kita Y, Funakoshi F, Nonomura T,
et al: Comparison study of the expressions of myristoylated
alanine-rich C kinase substrate in hepatocellular carcinoma, liver
cirrhosis, chronic hepatitis, and normal liver. Int J Oncol.
26:661–671. 2005.PubMed/NCBI
|
|
21
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: Procedure and some applications. Proc Natl
Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Reuveni H, Flashner-Abramson E, Steiner L,
Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M and Levitzki A:
Therapeutic destruction of insulin receptor substrates for cancer
treatment. Cancer Res. 73:4383–4394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tanaka S and Wands JR: Insulin receptor
substrate 1 overexpression in human hepatocellular carcinoma cells
prevents transforming growth factor beta1-induced apoptosis. Cancer
Res. 56:3391–3394. 1996.PubMed/NCBI
|
|
26
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu X, Tan D, Hou Z, Hu Z and Liu G:
miR-338-3p is down-regulated by hepatitis B virus X and inhibits
cell proliferation by targeting the 3′-UTR region of cyclinD1. Int
J Mol Sci. 13:8514–8539. 2012. View Article : Google Scholar
|
|
28
|
Fu X, Tan D, Hou Z, Hu Z, Liu G, Ouyang Y
and Liu F: The effect of miR-338-3p on HBx deletion-mutant
(HBx-d382) mediated liver-cell proliferation through CyclinD1
regulation. PLoS One. 7:e432042012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen L, Zheng J, Zhang Y, Yang L, Wang J,
Ni J, Cui D, Yu C and Cai Z: Tumor-specific expression of
microRNA-26a suppresses human hepatocellular carcinoma growth via
cyclin-dependent and -independent pathways. Mol Ther. 19:1521–1528.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang X, Liang L, Zhang XF, Jia HL, Qin Y,
Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, et al: MicroRNA-26a
suppresses tumor growth and metastasis of human hepatocellular
carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology.
58:158–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guo Y, Li S, Qu J, Wang S, Dang Y, Fan J,
Yu S and Zhang J: MiR-34a inhibits lymphatic metastasis potential
of mouse hepatoma cells. Mol Cell Biochem. 354:275–282. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li D, Liu X, Lin L, Hou J, Li N, Wang C,
Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits
hepatocellular carcinoma growth and correlates with prognosis of
patients with hepatocellular carcinoma. J Biol Chem.
286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
|
